Story · Medicine & Biotech

A New Cancer Vaccine Appears to Significantly Improve Survival in People in Remission From AML – MSK

2 outlets · first reported by OncoDaily on · latest · 28 hours of coverage

Memorial Sloan Kettering Cancer Center shared on LinkedIn: “A new cancer vaccine appears to significantly improve survival in people in remission from acute myeloid leukemia (AML), according to new results (OncoDaily)

Coverage, in order

  1. first OncoDaily obscure study
    A New Cancer Vaccine Appears to Significantly Improve Survival in People in Remission From AML – MSK

    Memorial Sloan Kettering Cancer Center shared on LinkedIn: “A new cancer vaccine appears to significantly improve survival in people in remission from acute myeloid leukemia (AML), according to new results

  2. Vinay Prasad indie explainer randomized trialn=122
    Does an AML vaccine improve survival from 14.7 to 24 months?

    The Washington Post is covering this small randomized study. The trial is 122 people. The vaccine is off the shelf. There's no personalization. It's an old, peptide technology. It's used in AML —one of the most challenging malignancy. We are told it improves overall survival from 14.7 to 24 months…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.